English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin lymphoma (T-NHL), are a biologically and clinically heterogeneous group of rare and aggressive neoplastic disorders that result from clonal expansion of lymphocytes committed to the T-cell lineage.1 Although the prognoses for T-cell malignancies have improved in recent years due to intensified combination chemotherapies, the outcome of patients with resistant or relapsed disease remains poor.2 Therefore, current research efforts are focused on more effective and less toxic targeted therapies, which will require an improved understanding of the molecular events underlying these malignancies.

Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies